| Methods |
1‐week washout (only for patients previously treated with anti‐hypertensive therapy); 2‐week single‐blind placebo run‐in; inclusion criteria= DBP 90‐109 mm Hg (which differed < 10mm Hg from that observed in previous visit) after run‐in; 6‐week double‐blind treatment |
| Participants |
All patients (per protocol population): n=342(137 males,205 females); mean age=55.6(9.9) years; baseline sitting SBP=158.3(10.6) mm Hg, DBP=98.6(5.3) mm Hg |
| Interventions |
Enalapril 5 mg once daily;
Enalapril 10 mg once daily;
Enalapril 20 mg once daily;
Placebo;
taken in the morning;
patients assigned to receive either 10 or 20 mg received 5 mg for the first week of treatment before titration to dose assigned |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer |
| Notes |
BP change and SD of change not reported, endpoint BP reported; endpoint SD not reported; baseline SD reported; imputed baseline SBP SD for SD of change; imputed overall trial mean DBP SD of change; BP data from Figure 1, p. 844; Jadad score=2; funding source= VITA INVEST |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
